Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Exp Hematol. 2009 Dec;37(12):1411-22. doi: 10.1016/j.exphem.2009.09.009. Epub 2009 Oct 6.
Polycythemia vera (PV) is characterized by erythrocytosis associated with the presence of the activating JAK2(V617F) mutation in a variable proportion of hematopoietic cells. JAK2(V617F) is detected in other myeloproliferative neoplasms, does not appear to be the PV-initiating event, and its specific role in deregulated erythropoiesis in PV is incompletely understood. We investigated the pathogenesis of PV to characterize abnormal proliferation and apoptosis responses and aberrant oncogenic pathway activation in primary PV erythroid precursors.
Peripheral blood CD34(+) cells isolated from PV patients and healthy controls were grown in liquid culture to expand a population of primary erythroblasts for experiments designed to analyze cellular proliferation, apoptosis, JAK2(V617F) mutation status, cytokine-dependent protein phosphorylation and gene expression profiling using Affymetrix microarrays.
The survival and proliferation of PV erythroblasts were growth factor-dependent under strict serum-free conditions requiring both erythropoietin (EPO) and stem cell factor. PV erythroblasts exhibited EPO hypersensitivity and enhanced cellular proliferation associated with increased EPO-mediated extracellular signal-regulated kinases 1 and 2 phosphorylation. EPO-induced AKT phosphorylation was observed in PV but not normal erythroblasts, an effect associated with apoptosis resistance in PV erythroblasts. Analysis of gene expression and oncogenic pathway activation signatures revealed increased RAS (p<0.01) and phosphoinositide-3 kinase (p<0.05) pathway activation in PV erythroblasts.
Deregulated erythropoiesis in PV involves EPO hypersensitivity and apoptosis resistance of erythroid precursor cells associated with abnormally increased activation of RAS-ERK and phosphoinositide-3 kinase-AKT pathways. These data suggest that investigation of the mechanisms of abnormal RAS and phosphoinositide-3 kinase pathway activation in erythroblasts may contribute to our understanding of the molecular pathogenesis of PV.
真性红细胞增多症(PV)的特征是红细胞增多,伴有造血细胞中存在激活的 JAK2(V617F)突变,其比例不定。JAK2(V617F)在其他骨髓增殖性肿瘤中被检测到,似乎不是 PV 的起始事件,其在 PV 中失调的红细胞生成中的具体作用尚未完全了解。我们研究了 PV 的发病机制,以描述原发性 PV 红细胞前体中异常增殖和凋亡反应以及异常致癌途径的激活。
从 PV 患者和健康对照者的外周血 CD34+细胞中分离出来,在液体培养中生长,以扩大原发性红细胞生成细胞群体,用于设计分析细胞增殖、凋亡、JAK2(V617F)突变状态、细胞因子依赖性蛋白磷酸化和基因表达谱的实验,使用 Affymetrix 微阵列。
在严格的无血清条件下,PV 红细胞的生存和增殖依赖于生长因子,需要促红细胞生成素(EPO)和干细胞因子。PV 红细胞表现出对 EPO 的超敏性和增强的细胞增殖,与 EPO 介导的细胞外信号调节激酶 1 和 2 磷酸化增加有关。在 PV 但不在正常红细胞中观察到 EPO 诱导的 AKT 磷酸化,这与 PV 红细胞的凋亡抵抗有关。基因表达和致癌途径激活特征分析显示,PV 红细胞中 RAS(p<0.01)和磷酸肌醇 3 激酶(p<0.05)途径的激活增加。
PV 中的失调性红细胞生成涉及红细胞前体细胞对 EPO 的超敏性和凋亡抵抗,与 RAS-ERK 和磷酸肌醇 3 激酶-AKT 途径异常增加的激活有关。这些数据表明,研究红细胞中异常 RAS 和磷酸肌醇 3 激酶途径激活的机制可能有助于我们理解 PV 的分子发病机制。